
Trump withdraws FDA commissioner nominee Heidi Overton, extending a leadership gap that leaves review and launch timelines uncertain for sponsors.
New technologies, along with changes in FDA oversight, may provide a critical path to make more new drugs available more quickly to patients.
over 22 years ago
In The Spotlight-May 2004over 22 years ago
Prepare for Bar Codingover 22 years ago
aaiPharma Situation Underscores The Need for Due Diligenceover 22 years ago
Excipient Functionalityover 22 years ago
May 2004





